Edition:
United States

Bausch Health Companies Inc (BHC.TO)

BHC.TO on Toronto Stock Exchange

28.99CAD
1:58pm EDT
Change (% chg)

$0.73 (+2.57%)
Prev Close
$28.26
Open
$28.75
Day's High
$29.07
Day's Low
$28.23
Volume
282,892
Avg. Vol
712,458
52-wk High
$36.52
52-wk Low
$23.60

About

Bausch Health Companies Inc, formerly Valeant Pharmaceuticals International Inc, is a Canada-based company that develops, manufactures and markets a range of branded and generic pharmaceuticals, medical devices and over-the-counter products. It primarily develops products in the therapeutic areas of eye health, gastroenterology... (more)

Overall

Beta: -0.36
Market Cap(Mil.): $5,024.01
Shares Outstanding(Mil.): 347.33
Dividend: --
Yield (%): --

Financials

  BHC.TO Industry Sector
P/E (TTM): -- 29.89 32.67
EPS (TTM): -3.27 -- --
ROI: -2.83 14.89 14.48
ROE: -24.78 16.01 15.78

Amag's female libido injectable therapy to sell at $899

Amag Pharmaceuticals Inc's treatment to boost sexual desire in premenopausal women will be offered at $899 and is the only injectable drug on the market for hypoactive sexual desire disorder (HSDD).

Aug 06 2019

UPDATE 1-Amag's female libido injectable therapy to sell at $899

Aug 6 Amag Pharmaceuticals Inc's treatment to boost sexual desire in premenopausal women will be offered at $899 and is the only injectable drug on the market for hypoactive sexual desire disorder (HSDD).

Aug 06 2019

Amag's female libido injectable therapy to sell at $899

Aug 6 Amag Pharmaceuticals Inc's treatment to boost sexual desire in premenopausal women will be offered at $899 and is the only injectable drug on the market for the condition.

Aug 06 2019

Teva loses challenge to Bausch patent on drug Relistor

Canadian pharmaceutical company Bausch Health Companies Inc (formerly Valeant Pharmaceuticals) on Wednesday won a ruling protecting its drug Relistor from U.S. generic competition from Teva Pharmaceuticals Industries Ltd.

Jul 18 2019

Bausch Health's lotion for plaque psoriasis wins FDA approval

The U.S. Food and Drug Administration on Thursday approved Bausch Health Companies Inc's topical plaque psoriasis treatment, which is expected to be a key revenue driver for the company.

Apr 25 2019

UPDATE 1-Bausch Health's lotion for plaque psoriasis wins FDA approval

April 25 The U.S. Food and Drug Administration on Thursday approved Bausch Health Companies Inc's topical plaque psoriasis treatment, which is expected to be a key revenue driver for the company.

Apr 25 2019

Bausch Health's lotion for plaque psoriasis wins FDA approval

April 25 Bausch Health Companies Inc said on Thursday the U.S. Food and Drug Administration has approved its lotion for plaque psoriasis in adults.

Apr 25 2019

Drugmaker Synergy says Ch. 11 plan has full support of key creditors

Gastrointestinal therapies developer Synergy Pharmaceuticals Inc will ask a judge on Tuesday to approve its plan to wrap up its bankruptcy and distribute proceeds from its $200 million sale.

Apr 22 2019

U.S. FDA loosens alcohol restrictions for female libido pill

The U.S. Food and Drug Administration said on Thursday women taking Sprout Pharmaceuticals Inc's female libido pill, Addyi, need not completely avoid alcohol.

Apr 11 2019

U.S. FDA loosens alcohol restrictions for female libido pill

April 11 The U.S. Food and Drug Administration said on Thursday women taking Sprout Pharmaceuticals Inc's female libido pill, Addyi, need not completely avoid alcohol.

Apr 11 2019
Reuters.com is improving our Quote page. Click here to take a look and let us know what you think.

Earnings vs. Estimates